05:31:44 EDT Tue 21 May 2019
Enter Symbol
or Name

Login ID:

Z:ABBV - ABBVIE INC - http://www.abbvie.com05:31:44 EDT
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
ABBV - Z0.579.35 · 79.980.379.82+0.360.54,395.5351,38437,70779.02  80.39  78.91107.25  75.62May 20 19:32:31May 1715 min RT 2¢

Recent Trades - Last 10 of 37707
Time ETExPriceChangeVolume

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent BulletinsNews ReleasesIn The NewsOther
Date ETSymbolTypeHeadline
2019-05-17 08:45U:ABBVNews ReleaseAbbVie Provides Update on Depatuxizumab Mafodotin (Depatux-M), an Investigational Medicine for Newly Diagnosed Glioblastoma, an Aggressive Form of Brain Cancer
2019-05-15 14:19U:ABBVNews ReleaseAbbVie Announces US FDA Approval of VENCLEXTA ® (venetoclax) as a Chemotherapy-Free Combination Regimen for Previously Untreated Chronic Lymphocytic Leukemia Patients
2019-05-14 10:13U:ABBVNews ReleaseMC10, Inc. and AbbVie (NYSE:ABBV) Announce Clinical Trials in Multiple Sclerosis Using the BioStamp nPoint ®  System
2019-05-14 08:34U:ABBVNews ReleaseAbbVie Resolves HUMIRA ® (adalimumab) U.S. Patent Litigation with Boehringer Ingelheim
2019-05-14 08:00U:ABBVNews ReleaseAbbVie to Present at the UBS Global Healthcare Conference
2019-05-07 08:00U:ABBVNews ReleaseAbbVie to Present at the Bank of America Merrill Lynch Healthcare Conference
2019-05-06 06:30U:ABBVNews ReleaseAlector Announces First Alzheimer ’s Disease Patient Dosed in Phase 1b Study of AL002
2019-04-30 07:45U:ABBVNews ReleaseEuropean Commission Approves SKYRIZI ™ (risankizumab) for the Treatment of Moderate to Severe Plaque Psoriasis
2019-04-30 07:08U:ABBVNews ReleaseAbbVie to Present New and Updated Data of Investigational Medicines for Parkinson's Disease and Multiple Sclerosis at 2019 American Academy of Neurology Annual Meeting
2019-04-25 07:42U:ABBVNews ReleaseAbbVie Reports First-Quarter 2019 Financial Results
2019-04-23 18:19U:ABBVNews ReleaseAbbVie Expands Immunology Portfolio in the U.S. with FDA Approval of SKYRIZI ™ (risankizumab-rzaa) for Moderate to Severe Plaque Psoriasis